ATMPS Ltd has created the Hataali platform which digitises the end to end, cell and gene therapy process, providing immutable digital records with full chain of custody, identity and condition data. It can be used for clinical trials and commercially available therapies.

Hataali allows clinics, pharmaceutical companies, and couriers to communicate and coordinate their activities in real time. Hataali is modular and interoperable, integrating existing systems. It is patented and future-proof utilising blockchain technology.

Hospitals can digitally enrol and screen patients and order multiple treatments from multiple pharmaceutical companies through a single portal.

Pharmaceutical companies can easily administer, monitor and schedule treatments to multiple clinics in multiple countries, over one platform. Our digital analytics dashboards provide data driven decision making capabilities.

The Hataali platform significantly reduces implementation times and costs to users of the cell and gene therapy ecosystem. It increases efficiency, ensures patient safety and provides regulatory compliance.

Germfree creates environments that serve life science innovation and advance global health. Germfree designs and manufactures flexible cGMP-compliant cleanroom buildings and high-containment facilities which are process or containment-ready upon deployment. Our facilities are designed to integrate with Germfree’s core equipment including our lines of interchangeable laminar flow hoods and containment equipment. Established in 1962 Germfree’s leading-edge fabrication technology, engineering teams and subject-matter experts are located at our 173,000 square foot (16,000 square meter) US manufacturing plant with installations in operation around the world.

Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, believes in the potential of blood and cells to do even more for patients than they do today. Terumo Blood and Cell Technologies’ business enables researchers, developers and manufacturers to create next-generation cell and gene therapies. We do this through flexible, automated solutions that help meet your evolving needs for reproducibility, quality and scale through the phases of development, from translational research to current good manufacturing practice (cGMP) for commercial manufacturing. One example, the Quantum’ Cell Expansion System, automates and optimizes cell culture to meet the needs of a variety of cell types in a consistent, controlled and functionally closed environment. We are also looking further downstream in the process to provide innovative solutions, like the Finia’ Fill and Finish System, to support your needs into the future.

Cognate BioServices is the leading CDMO for the development and manufacturing of autologous and allogeneic cell and gene therapy products. We are a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development specializing in mid to late stage clinical trials and supporting our clients through product scale-up into commercial manufacturing. Cognate applies the knowledge and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish.

Akron Biotech drives advanced therapy development and commercialization with high quality, industrial scale solutions. Akron’s strategic focus is supplying GMP-compliant ancillary materials and services to enable the advancement of cell and gene therapies. These include cytokines and growth factors, human sera and purified proteins, cryopreservation solutions, and custom development services. Beyond our pharmaceutical grade products, Akron is committed to providing solutions to our customers, with personalized service. An ISO 13485-certified company operating in line with cGMP guidelines and international standards, Akron provides advanced therapy developers the scale, compliance, and regulatory support to develop novel treatments.

The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. With over 400 experts covering all aspects of advanced therapies, it applies its unique capabilities and assets, collaborates with academia, industry and healthcare providers to develop new technology and innovation. The Cell and Gene Therapy Catapult works with Innovate UK.